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Abstract
Background: Ocular Chlamydia trachomatis (Ct) infection causes trachoma, the leading infectious cause of
blindness. A Ct D/UW3 proteome microarray and sera from Gambian adults with trachomatous trichiasis (TT) or
healthy matched controls previously identified several novel antigens, which suggested differential recognition in
adults with TT.
Methods: We re-analysed this serological microarray data using more robust microarray analysis techniques
accounting for typical problems associated with highly dimensional data. We examined the Ct-specific antibody
profile concerning the overall diversity of responses, antigen expression stage and cellular localisation of antigens.
We tested differentially recognised antigens by further serological testing of the screened sera and used larger
independent sample sets for validation.
Results: Antibody responses identified High-Performance on antigens expressed early and late in the Ct
developmental cycle and those secreted or localised to the outer membrane. Eight antigens were preferentially
recognised by scarred individuals and one antigen by healthy individuals. Three of these antigens, two associated
with scarring (CT667 and CT706) and one healthy-associated (CT442), were not associated with the presence or
absence of scarring following specific serological testing of the arrayed sera and sera from larger, independent
case-control cohorts.
Conclusions: This study identified focussed Ct-specific antibody profiles targeting proteins expressed during entry
and exit from cells and localised to interact with the host. A small panel of antibody responses could discriminate
between adults with and without TT in a trachoma-endemic community. Heterogenous responses in the
independent validation of these antibody targets highlighted the need for large sample sizes, clearly defined
clinical phenotypes and follow-up work.
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Background
Trachoma, caused by ocular infection with Chlamydia
trachomatis (Ct), is the leading infectious cause of blind-
ness worldwide. Ocular infections with Ct affect the epi-
thelial cells of the conjunctiva [1], with repeated infection
in endemic areas causing a chronic keratoconjunctivitis [2,
3]. Chronic and repeated episodes of infection and disease
in children induce changes in the tissue underlying the
conjunctiva, leading to deposition of scar tissue. Progres-
sion of this scarring pathology can lead to trichiasis (TT),
corneal opacities (CO) and blindness [4]. The majority of
people in trachoma-endemic communities do not pro-
gress to these latter stages of trachomatous disease and
pathology varies considerably within those that do pro-
gress. This heterogeneity seems, in part, due to the impact
of prolonged infection and inflammation; however other
risk factors have also been identified including age, gender,
dry eye and non-chlamydial bacteria [5–13].
Levels of IgG antibodies against Ct elementary bodies
(EBs) are significantly higher in individuals with scarring
trachoma [14–16]. Since frequent and persistent infections
are associated with scarring, this suggests the development
of these antibodies does not protect from progression. One
of these studies found higher levels of antibody against the
Ct antigen HSP60 in scarring individuals independent of re-
sponses against EBs, implying HSP60 is not simply a
marker of increased exposure. This association of anti-
HSP60 antibodies was not consistent between studies of
trachomatous scarring (TS) and trachomatous trichiasis
(TT) [17, 18]. However, one of these studies did demon-
strate that IgG antibodies against another Ct antigen, CPAF,
were significantly increased in TT [18]. It is unclear
whether the scarring-associated antibody responses identi-
fied in trachoma-endemic communities are common
throughout the population or if they are directly involved
in the scarring process. It is possible via opsonisation that
anti-Ct antibodies could facilitate greater Ct infectivity in
young children promoting frequent and prolonged
infections that are known to be a risk factor for TS/TT.
Equally, they may be coincidental serological markers of
infection.
The last decade has seen the exploitation of protein-
based screens of human serum to document the complete
profile of antibody responses stimulated by an infection
[19]. This has streamlined the identification of diagnostic
and vaccine candidates, leading to faster progression
and evaluation of individual targets. For Plasmodium
falciparum and malaria, targeted panels of proteins
have been screened to identify immunity-associated
antigens [20] and antigens associated with particular
stages of infection [21]. Similar studies have been
applied to some bacterial species including Mycobac-
terium tuberculosis [22] and 30 causative organisms
of tropical infectious diseases [23].
There have been six published studies that have screened
human serum against microarrays of Ct antigens to define
serological responses [24–27], two of these simultaneously
investigated T-cell responses [28, 29]. A comparison of
these studies (summarised in Additional file 1: Table S1),
identifies some commonly recognised antigens. However,
the majority were identified in only one or two studies. This
variation likely represents methodological differences and
heterogeneity in immune responses targeting Ct antigens.
A similar murine study found more focussed serological
responses in C57/BL6 mice which are more resistant to
urogenital chlamydial infection than BALB/c and C3H/
HeN mice, suggesting variations in susceptibility to infec-
tion are partly related to antibody profiles [30].
Previously, serum from individuals with TT was used
to screen a Ct D/UW3 proteome array of 908 genomic
and plasmid ORFs [31]. This study used 61 cases of
trichiasis (TT) and 61 age, sex and location-matched
controls with normal healthy (healthy) eyes collected in
The Gambia between May 2006 and February 2009.
Thirty-four cases and 25 controls were screened on the
serovar D Ct proteome array [24, 25]. Ten antigens were
recognised by > 50% of the 59 samples tested. Four anti-
gens were preferentially recognised by those with TT
and eight by healthy controls (Table 1). However, there
were some limitations in the study including in both the
wet and dry lab study methodologies. The small sample
size, lack of global normalisation and inadequate mea-
sures to control against false discovery each contributed
to a high chance of error [32].
Here, we report the results of a more robust biostatis-
tical analysis of data generated from this array. We then
determined differences in response diversity, richness
and evenness by employing standard metrics used in
ecology and analysis of 16S-amplicon community sur-
veys. We additionally utilised sera from independent
studies of TS/TT to demonstrate the need for validation
of antibody responses determined using large-scale
screening of small numbers of participants.
Methods
Study participants
Sera were taken from three clinical cohorts collected in
The Gambia between 1995 and 2011. In 1995, 153
Table 1 Participant demographics from the study of TS and
matched controls from The Gambia in 1995. Age (generalised linear
model) and gender (Fisher’s exact test) were compared between
healthy controls and scarred cases, associated P-values are indicated
Healthy controls Scarred cases P-value
Number 116 115 na
Age in years (95% CI) 37.50 (7.00–65.00) 38.00 (7.00–65.75) 0.900
Female, n (%) 84 (72.41) 80 (69.57) 0.633
Abbreviation: na not applicable, CI Confidence intervals, n number
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people with evidence of TS by clinical examination were
recruited alongside age, sex and village-matched controls
with normal eyes from Kaur Health Centre and the vil-
lages of Jali and Berending (SCC729). A 1 ml sample of
venous blood was taken from each person to obtain
serum [33, 34]. A total of 231 serum samples were re-
tested from this study in the present analysis (Table 1).
Between May 2006 and February 2009, 61 people with
evidence of TT and corneal opacities (CO) by clinical
examination were recruited alongside age, sex and
village-matched controls with normal eyes from the
Western, Central and Lower River Regions of The
Gambia (SCCL2006.10). A sample of venous blood was
taken from each person to obtain serum. Details of the
cohort and the collection are available in Lu et al. [31].
A total of 116 of these archived sera were available for
testing by the present study (Table 2). Thirty-four cases
and 25 controls were screened on the serovar D Ct
proteome array described previously [31]. Briefly, 59 in-
dividuals with high titres of anti-Ct ocular serovar anti-
bodies were selected, removing individuals with
presumed low anti-Ct antibody levels. Serum samples
were screened against a GST-fusion protein micro-array
of 908 ORFs from Ct D/UW3.
In 2011 (SCC1274), 90 people with evidence of TS and
TT by clinical examination were recruited alongside age,
sex and village-matched controls with normal eyes from
multiple rural regions [35] (Table 3). A 1 ml sample of
venous blood was taken from each person to obtain
serum, sera from all 90 patients were available for testing
in the present study.
Normalisation, filtering and positivity
The raw optical density data from the microarray
(Additional file 2: Table S2) was transformed by in-
verse hyperbolic sine transformation and normalised
by mean-centring, these techniques were determined
as the most suitable ‘normalisation’ step using rele-
vant rank deviation (RRD) [36]. Post-normalisation,
the global median of the data, was calculated, individ-
ual antigens whose median was lower than the global
median were excluded.
Lu et al. defined a positive response as an optical density
(OD) equal to or greater than two standard deviations
above the mean from the relevant 96-well plate [31]. How-
ever, there is no consensus method to differentiate at
which point a response or value is judged to be signifi-
cantly positive in serological microarrays. In this reanaly-
sis, we, therefore, tested several different methods to
identify positive-negative breakpoints in the distribution
of the data [37]. These were: k-means clustering, k-
medoids clustering, fuzzy c-means clustering, hierarchical
clustering and mixture modelling. These were tested
allowing for 2 to 10 clusters. Maximisation of between
cluster variance was favoured over minimisation of
within-cluster variance. Silhouette analysis was selected to
quantify the effectiveness of clustering methods. The aver-
age silhouette width of each antigen was used to deter-
mine the appropriateness of the cluster configuration [38].
The mean of each silhouette per antigen gave the average
silhouette width, which illustrates how tightly the data
were plate array. To determine positive responses, two
Lyophilized were identified and the method that resulted
in the highest average silhouette width for each antigen
identified. Data points clustered with the maximum OD/
signal intensity point of each antigen were considered
positive and the opposing cluster negative.
Diversity metrics
Ecological measures of diversity rely on species breadth/
richness, the total number of species in a sample, and spe-
cies diversity, which additionally incorporates the relative
abundance of each species. We treated antigens as species,
abundance as the response to each antigen and the sam-
ples were either the entire data set or the data set split
into dichotomous outcome variables. These definitions
are based on the assumption that responses on the array
correlate with abundance of antibodies in each sample. A
normalised OD= 1 some as one arbitrary unit of an anti-
body. This means if a response to an antigen is twice as
high in one sample compared with another, antibodies are
twice as abundant in that individual.
Breadth was defined as the number of antigens to which
each had a positive response. For the remaining measures
examining diversity, existing methods were exploited by
Table 2 Participant demographics from the study of TT and
matched controls collected between May 2006 and February
2009 in The Gambia. Age (generalised linear model) and gender
(Fisher’s exact test) were compared between healthy controls
and scarred cases, associated P-values are indicated
Healthy controls Scarred cases P-value
Number 58 58 na
Age in years (95% CI) 55.50 (30.43–73.73) 60.00 (34.00–77.88) 0.199
Female (n [%]) 40 (68.97) 39 (67.24) 0.842
Abbreviation: na not applicable, CI Confidence intervals, n number
Table 3 Participant demographics from the study of TT/CO and
matched controls from The Gambia in 2011. Age (generalised
linear model) and gender (Fisher’s exact test) were compared
between healthy controls and scarred cases, associated P-values
are indicated
Healthy controls Scarred cases P-value
Number 38 52 na
Age in years (95% CI) 19.50 (1.00–39.00) 20.50 (3.55–37.73) 0.224
Female, n (%) 30 (78.95) 45 (86.54) 0.343
Abbreviation: na not applicable, CI confidence intervals, n number
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utilising the continuous OD/signal intensity values. This
was deemed more appropriate as an assumption of these
methods was that individuals within a species are equiva-
lent [39, 40], in this analysis the species are antigens, and
positive responses to them are not equal.
We utilised two different measures of diversity to im-
prove the reliability of the results. Shannon’s entropy (H)
and Simpson’s index (D) [40]. Higher values for both in-
dicate increased diversity and greater evenness. High
values of H mean that an unknown individual could be-
long to any species. In our context, this means one unit
of antibody in a sample could be targeted against any
antigen because responses in the sample are equivalent
[41]. High values of D mean that two randomly chosen
individuals are likely to be from different species. In our
context, this means two separate units of antibody from
the array are unlikely to be targeted against the same
antigen due to evenness of the responses [41].
Recombinant protein expression and peptide synthesis
Pgp3, CT667 and CT706 GST-fusion Ct constructs were
provided by Professor Guangming Zhong (UT Health Sci-
ence Center, San Antonio, TX) and were produced as previ-
ously described [24]. Briefly, 1 L of 2x YT media was
inoculated with frozen stocks of transformed E. coli and in-
cubated at 37 °C overnight at 230 RPM. Overnight cultures
were diluted into 2× YT media and incubated at 37 °C at
230 RPM until OD 600 reached 0.6 to 1.2. IPTG was added
at a concentration of 200 μM to induce expression and in-
cubated at 30 °C for three h. Cultures were centrifuged at
4 °C for 30 min at 4000× g, and the harvested cells were re-
suspended in 1:20 culture volume of phosphate-buffered sa-
line (PBS) with protease inhibitors. The bacteria were lysed
by mechanical cell disruption followed by centrifugation at
4 °C for 30 min at 4000× g to remove aggregated material
and cell debris. Relevant detergents were added, 1% (v/v)
Triton X-100 for Pgp3 and CT667 and 1% (w/v) ASB-14
for CT706, and the samples incubated at room temperature
for 2 h on a roller. The samples were centrifuged at 4 °C
for 1 g at 12,000× g, and the supernatants containing sol-
uble proteins and stored at -20 °C.
To affinity purify proteins 1:2000 culture volume of a
50% slurry of glutathione Sepharose beads was added to
the soluble protein samples to bind the GST moiety and
the mixture incubated at room temperature for 2 h on a
roller. The samples were passed down a 5 ml polypropyl-
ene column leaving a bed of GST-fusion bound beads. To
cleave the GST-fusion before purification, the beads were
washed. The correlation times with 5 ml cleavage buffer
before adding 1:4000 culture volume cleavage buffer with
8% (v/v) PreScission Protease (GE Healthcare Life Sci-
ences, Little Chalfont, UK) and incubated at 4 °C over-
night. The eluates were collected, and the elution step
repeated twice. Cleaved recombinant proteins were
further purified by size-exclusion based gel-filtration chro-
matography using a 35 ml Superdex 200 column (GE
Healthcare Life Sciences) with a ÄKTApurifier.
Biotinylated peptides of CT442 were produced by think-
peptides (ProImmune, Oxford, UK), using sequences from
Ct D/UW3. Purity High-Performance by High Perform-
ance Liquid Chromatography (HPLC), the minimum ac-
cepted was 80%. Lyophilized peptides were resuspended
in distilled H2O, aliquoted and stored at -80 °C. The
CT442 peptide sequence (amino acid 135–150) had been
previously identified as immunogenic (Dr Bernhard
Kaltenboeck, personal communication) [42].
ELISA testing
The initial ELISA protocol was adapted from methods used
previously in trachoma or urogenital Ct infection [18, 24].
The protocol was validated by comparing the results with
two published Pgp3-based ELISA protocols [43, 44]. Recom-
binant proteins were diluted to 1 μg/ml in coating buffer
(0.05 M carbonate-bicarbonate in PBS at pH 9.6) and 50 μl/
well added to the first 90 wells of Immulon 4 HBX microti-
tre plates (Fisher Scientific, Loughborough, UK). The posi-
tive control antigen Pgp3 was similarly diluted and added to
the remaining 6 wells of each plate as a positive control. An-
tigens were bound at 4 °C overnight. Sera/plasma were di-
luted 1:500 in blocking buffer [0.05% (v/v) Triton X-100 and
2.5% (w/v) skimmed milk in PBS at pH 7.5]. Four hyper-
immune control sera were pooled and diluted 1:100 and
then serially diluted 1/5, 5 times. After 30 min agitation, di-
luted samples were stored at 4 °C overnight.
The following day plates were inverted and washed
twice with washing buffer [0.05% (v/v) Triton X-100 in
PBS at pH 7.5] and blocked at room temperature for 4 h.
After 2 washes 100 μl test sera in triplicate and control
sera were added and incubated at room temperature for
4 h. After 4 washes, 100 μl anti-human IgG-peroxidase
antibody diluted 1:30000 in blocking buffer was added per
well and incubated at room temperature for 1 h. After a
final 4 washes, 100 μl 1-Step Ultra TMB-ELISA substrate
(Fisher Scientific, Loughborough, UK) were added per well
and incubated at room temperature for 10 min. The reac-
tion was stopped by addition of 100 μl 2 M sulphuric acid
per well, and the plate read at OD 450 nm for detection
and 700 nm for background correction.
Biotinylated peptides were tested using a modified proto-
col. Stocks of streptavidin were diluted to 5 μg/ml in H2O,
and 100 μl/well added to the first 90 wells and Pgp3 was
added to the remaining 6 wells on each plate as described
above. Streptavidin and Pgp3 were dried onto the plates by
incubation, uncovered, at 37 °C overnight. Sera/plasma was
diluted 1:250. The following day the plates were rehydrated
with washing buffer at room temperature for 15 min. Bio-
tinylated peptides were diluted to 1 μg/ml in peptide coat-
ing buffer (0.1% bovine serum albumin (BSA) and 0.1%
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sodium azide in PBS at pH 7.5), and 50 μl/well added to
the first 90 wells, blocking buffer was added to the
remaining 6 wells of each plate. Peptides were bound to
streptavidin at room temperature for 1 h with agitation.
After 2 washes plates were blocked at room temperature
for 30 min. After 2 washes the antibody binding and detec-
tion were performed as above.
Non-specific absorbance at OD 700 nm was subtracted
from absorbance at 450 nm, samples in triplicate were av-
eraged and values greater than 1 standard deviation from
the mean excluded. If two out of three repeats were
greater than 1 standard deviation from the mean, samples
were retested. Values from each positive control dilution
were averaged across all plates for each sample set. Values
from each plate were divided by the averaged values, the
mean deviation for each plate’s serial dilution from the
average was used to transform each plate’s values.
Statistical and in silico analyses
All comparisons were between scarring cases (TT and
CO) and healthy matched controls unless otherwise
stated. The intensity of responses was compared using a
Fig. 1 Over-representation of late and very early expressed proteins and extracellular, outer membrane and periplasmic proteins in immunogenic
antigens. a Proteins identified through transcriptomics as expressed late or very early in the Ct developmental cycle were over-represented in the 230
immunogenic antigens (light grey) compared with the total unfiltered 908 (dark grey). b Proteins with a consensus localisation prediction of extracellular,
outer membrane and periplasm were over-represented in the 230 immunogenic antigens (light grey) compared with the total unfiltered 908 (dark grey).
Error bars represent standard deviation
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generalised linear model (glm) and number of positive
responses using Fisher’s exact test. For the glm analysis,
10,000 permutations of the outcome variable were per-
formed to generate an adjusted P-value (P*), controlling
for type-1 error. Likelihood ratio tests were used to com-
pare models with null models only including the covari-
ates, age and gender.
Developmental cycle expression stage for each tran-
script was based on data and groupings from Belland
et al. [45], this grouping was manually assigned to
data from Nicholson et al. [46]. Localisation of
expressed proteins was predicted using Cello [47],
pSORTB [48] and loctree3 [49], three of the top per-
forming prediction tools for bacterial proteins [49].
Predicted localisation was defined as the consensus
from the 3 tools.
Results
Antibody responses are focussed on antigens expressed
early and late during the developmental cycle and
localised to interact with the host
After normalisation and filtering out of infrequently recog-
nised antigens, responses of 59 individuals against 230 anti-
gens were included in the analyses. Binary classification of
positive and negative samples per antigen was achieved
using the most appropriate clustering method, determined
by average silhouette width (Additional file 3: Figure S1).
Comparing the 230 antigens remaining after filtering with
the 908 proteins screened on the array indicated, there was
a significant over-representation of genes whose peak ex-
pression is either very early or very late in the developmen-
tal cycle, likely representing antigens important in cell entry
and those exposed at exit, P-values 0.003 and 0.025 (Fig. 1a).
Fig. 2 No significant differences in diversity of antibody responses between adults with and without scarring. Diversity was measured using Simpson’s
diversity index (D-1) (a) and Shannon’s diversity index (H) (b). Median (red lines) and notches were calculated as the median +/- 1.57 x IQR/sqrt of n,
where IQR is the interquartile range and n is the number of samples. The IQR times 1.5 was added to the 75th percentile and subtracted from the
25th percentile to determine the whiskers. Dots are outliers
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Notably, proteins predicted to be extracellular/secreted, or
localised to the outer membrane and periplasm were also
over-represented in the immunogenic antigens, P-value <
0.001 (Fig. 1b).
Next, we utilised the global profile of antibody responses
in scarred and healthy individuals to identify differences in
diversity or evenness of responses. The breadth of re-
sponse tended to be higher in scarred individuals however
it was highly variable and did not reach significance, P-
value 0.620. Simpson’s diversity index was skewed by a
few individuals with very focused responses and showed
no difference between groups, P-value = 0.451 (Fig. 2a).
Shannon’s diversity index, similar to measures of breadth,
tended to be lower in healthy individuals but the differ-
ence was not significant, P-value = 0.130 (Fig. 2b).
Individual antibody responses are associated with
conjunctival scarring
Association between participant’s evidence of conjunc-
tival scarring and antibody responses against each anti-
gen was determined using a generalised linear model
adjusting for age and gender of the individuals. Nine
differential antibody responses were identified between
adults with and without scarring, permuted P-values ≤
0.1 were permitted to include antigens outside the 95%
distribution that were close to the P* = 0.05 threshold
for significance (Table 4). All antigens except CT442 had
higher responses in scarred individuals. Three of these
antigens were identified by Lu et al. [31], nine antigens
identified as differentially recognised by Lu et al. [31]
were not supported by this re-analysis (Table 5).
Independent follow-up of array-defined serological
responses
To validate the antigens recognised in the microtitre plate
array, three antigens were selected for further testing by
ELISA. CT442 was selected for follow-up because of its
potentially interesting intracellular biology as an inclusion
membrane protein (Inc) known to induce T-cell responses
and the only antigen with greater antibody responses in
healthy individuals [50]. CT667 was selected as a
homologue of CdsG, a conserved bacterial protein in-
volved in type-three secretion (T3S) [51]. Homologues of
CT667 in other bacteria act as a chaperone for the T3S-
needle protein and in Ct CT667 has been localised to the
host cytosol and around the inclusion membrane, depend-
ing on host cell type and stage of the Ct developmental
cycle [52]. CT706 was selected as a homologue from C.
muridarum and has previously been identified as im-
munogenic. These three were the only antigens identified
as differentially recognised in the initial analysis [31], all of
which were available as GST-fusion proteins. Pgp3 was in-
cluded as an immunodominant positive control.
The selected antigens were retested on 59 sera screened
in the array, excluding one sample for which we no longer
had serum, and the complete set of 116 sera available
from the original study [31]. The positive control anti-
Table 4 Differentially recognised antigens between adults with
and without scarring. Univariate associations were determined
using a generalised linear model. Variables were resampled
10,000 times and remodelled to determine permuted P-values
(P*). The t-statistic (t) and its standard error, SE(t), are indicated.
The odds ratio (OR) and 95% confidence interval (95% CI) of an
individual having TT associated with a 1 unit increase in OD are
indicated. Area under curve (AUC) for predicting TT status from
a generalised linear model including each antigen are indicated
Antigen P-value P* t SE(t) OR 95% CI AUC
CT667 0.013 0.005 0.78 0.32 2.19 1.28–4.43 0.64
CT645 0.036 0.029 0.56 0.27 1.76 1.09–3.16 0.63
CT314 0.040 0.012 0.42 0.21 1.52 1.09–2.43 0.66
CT698 0.049 0.037 0.55 0.28 1.72 1.05–3.16 0.59
CT471 0.051 0.023 0.59 0.30 1.80 1.08–3.49 0.62
CT442 0.054 0.019 -0.12 0.06 0.89 0.77–0.98 0.63
CT679 0.057 0.011 0.66 0.35 1.94 1.11–4.28 0.61
CT425 0.070 0.049 0.51 0.28 1.66 1.04–3.16 0.54
CT706 0.098 0.064 0.32 0.19 1.37 1.03–2.19 0.57
Table 5 Agreement of differentially recognised antigens identified
previously by Lu et al. [31] and in this study. The agreement, or
disagreement, between the two analyses on antigens recognised
more frequently or strongly by individuals with (scarred) or without
(healthy) trachomatous scarring and trichiasis is indicated by ‘Yes’ or
‘No’ on the final column. Kappa = 0.25
Antigen Lu et al. [31] This study Agreement
CT019 Healthy None No
CT117 Healthy None No
CT301 Healthy None No
CT314 None Scarred No
CT414 Scarred None No
CT425 None Scarred No
CT442 Healthy Healthy Yes
CT471 None Scarred No
CT553 Healthy None No
CT556 Healthy None No
CT571 Healthy None No
CT645 None Scarred No
CT667 Scarred Scarred Yes
CT679 None Scarred No
CT695 Healthy None No
CT698 None Scarred No
CT706 Scarred Scarred Yes
CT709 Healthy None No
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Pgp3 results from the ELISA were strongly correlated with
those from the array (rho = 0.91, P-value < 0.001) (Fig. 3).
CT442, CT667 and CT706 had significant but weak
correlations between array values and follow-up testing
by ELISA (Fig. 4). All three trended towards the same
healthy or scarring-association identified from the
microarray. However, only CT667 was significantly asso-
ciated with scarring (P-values; CT442 = 0.252, CT667 =
0.024 and CT706 = 0.169). None of these differentially
recognised antigens was associated with healthy or
scarred individuals when tested on the complete set of
116 samples, with p-values of 0.368, 0.169 and 0.289
respectively. The strongest responses to CT442 and
CT667 were found in healthy individuals, but no clear
association with protection was found.
Independent serological testing of antibody targets
associated with conjunctival scarring
These studies were cross-sectional collections of cases
with scarring and matched controls. These sera were
tested for antibody responses against the three differen-
tially recognised antigens to determine if they were asso-
ciated with scarring in independent studies from related
trachoma-endemic communities.
All three antigens showed mixed or minimal associ-
ation with scarring (Table 6). CT667 and CT706 anti-
body responses were not associated with scarring in
either cohort. CT442 was significantly associated with
scarring in adults from the Gambian study from 2011
which was inconsistent with its association with healthy
adults from the microtitre plate array results.
Discussion
In this study results from a microplate array used to screen
sera from a case-control study of Gambian adults with scar-
ring trachoma for Ct-specific antibody responses were re-
analysed. We found that antibody responses were focussed
on secreted, outer membrane and periplasmic proteins.
There was a trend towards less diverse global antibody re-
sponses in adults without conjunctival scarring. Heightened
responses to 8 antigens were associated with the presence
of scarring, only antibody responses to CT442 were associ-
ated with a lack of scarring. Three of these differentially
recognised antigens were concordant with previous analysis
of this micro-plate array. Association of antibody responses
against these three antigens with scarring was assessed by
further independent serological testing. CT667 and CT706
were not associated with scarring in adults in independent
case-control studies from The Gambia. CT442 responses
were not associated with an absence of scarring in adults in
the independent studies.
Global antibody profiles indicate common targeting of
responses in adults
The number of immunogenic antigens, those that passed
initial filtering, and the number of commonly recognised
antigens, determined by breadth, were both low. This
likely reflects the reduced frequency and duration of Ct
infection and active trachomatous disease in older individ-
uals. It also suggests a time dependent focusing of
antibody responses. These individuals experience a life-
time of exposure to Ct promoting selective activation and
maintenance of high-affinity antibodies. As frequency and
duration of Ct infection decrease, the opportunity for
Fig. 3 Pgp3 correlation between ELISA and array results. Responses to Pgp3 were retested in 59 arrayed serum using and in-house ELISA.
Correlation between ELISA and array results was high. A linear model of results from the ELISA and array was used to fit the line (red)
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restimulation of Ct-specific plasma cells may be reduced.
While some of these Ct-specific cells may be maintained
as long-lived plasma cells, reactivation by abundant and
immunogenic Ct antigens favours survival and expansion
of specific plasma cells. This can put antigens commonly
exposed to the extracellular space and B-cells at a selective
advantage. Antibodies specific to these antigens are more
likely to be activated during infrequent episodes of Ct in-
fection, promoting their activation and affinity maturation.
This more focused profile of antibody responses was
reflected in the common recognition of antigens
expressed at similar stages of chlamydial development or
their cellular localisation.
The recognition of proteins expressed very early and
late in the Ct developmental cycle was over-represented.
It is during these periods that Ct, in the form of infec-
tious EBs, is most exposed to the humoral immune sys-
tem. Potential targets may be EB outer membrane
proteins, proteins in the membrane of extrusions
[53] and a more unpredictable group of proteins exposed
to the extracellular environment upon Ct lytic exit from
cells. This was supported by the over-representation of
Fig. 4 CT442, CT667 and CT706 correlation between ELISA and array results. Responses to CT442 (a), CT667 (b) and CT706 (c) were retested in 59
arrayed serum using an in-house ELISA. Correlation between ELISA and array results was poor for CT442 (rho 0.26, P = 0.046). Correlation between
ELISA and array results for CT667 and CT706 were moderate (rho 0.59 and 0.58, both P < 0.001). A linear model of results from the ELISA and array
was used to fit the line (red)
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the chlamydial outer membrane, extracellular and peri-
plasmic proteins in the complete list of immunogenic
antigens.
The diversity of antibody responses was not signifi-
cantly different between adults with and without trach-
omatous scarring. There was a trend towards increased
diversity in scarred adults by Shannon’s diversity index,
but this was not supported by Simpson’s diversity index.
This reinforces the finding that adults, in general, had
focussed antibody responses.
Few antigens are differentially recognised between
individuals with and without scarring trachoma
There was no difference in the diversity profile of
antibody responses between adults with and without
scarring. However, a small panel of antigens was differ-
entially recognised between these groups. Antibody re-
sponses to eight antigens were associated with scarring
and responses to a single antigen were associated with a
lack of scarring. The low number of differentially
recognised antigens supports a focusing and reduced
heterogeneity of antibody responses in older individ-
uals. Three of these antigens were identified as differ-
entially recognised in the analysis by Lu et al. [31]:
CT442, CT667 and CT706. Of the seven antigens
previously identified that were not supported follow-
ing independent analysis, six had been originally dif-
ferentially associated by Fisher’s exact test comparing
the number of positive responses between adults with
and without scarring. A more objective definition of
positivity was used in the follow-up independent ana-
lysis leading to no significant differentially recognised
antigens being identified.
Limited published information was available for these
antigens. CT314, CT425 and CT442 have been identified
as immunogenic in patients with urogenital Ct or related
disease [25], and mouse models have shown CT442 is a
target of CD8+ T-cell responses [50]. No functional stud-
ies of these antigens have been undertaken, although
some of them share homology with bacterial proteins of
known functions. These relate to cell division (CT471
and CT697), transcription (CT314), protein quality
control (CT706) and type-3 secretion (CT667). These
homologues and localisation predictions suggest they
likely reside within the inclusion, meaning they would
only be exposed to B-cells upon cell lysis. There is
evidence that some of these targets may be more easily
accessible to the host immune system. Proteomic ana-
lysis of Ct EBs identified CT314 as a component of the
outer membrane complex [54]. CT442 has been local-
ised to the inclusion membrane [50] at early stages of
the Ct developmental cycle, CT667 appears to reside in
the cytosol [52].
Validation of large-scale array-based methods is essential
Responses against the positive control Pgp3 were strongly
correlated between the array and in-house ELISA. The
correlation was strong for the differentially recognised
CT667 and CT706 but not CT442, although the latter
was tested using a short peptide rather than a full-length
recombinant. A caveat to the lack of identification of some
immunodominant antigens on the array, such as MOMP
and the majority of polymorphic membrane proteins
(pmp) is their poor immunogenicity since they did not
pass initial filtering of recognised antigens. PmpC
(CT414) and PmpD (CT812) were the only Pmp’s fre-
quently recognised and both were expressed as fragments,
not full-length proteins. This suggests large, multimeric
proteins such as these should be expressed as fragments
or peptides alongside full-length proteins in microarrays.
Antibody responses associated with conjunctival scar-
ring (CT667 and CT706) or an absence of conjunctival
scarring (CT442) from the array analysis were not sup-
ported in the complete set of sera or the two further sets
Table 6 ELISA results from the complete 116 sera and two further scarring case-control studies. The three arrayed antigens were
tested on the complete set of 116 sera (2006), 231 samples from a previous scarring case-control study in The Gambia (1995) and a
subsequent scarring case-control study in The Gambia (2011). CT442 showed no association with the absence of scarring, and
CT667/CT706 were not associated with scarring
Antigen Sera Healthy median (IQR) Scarred median (IQR) P-value OR (95% CI)
CT442 2006 0.24 (0.19–0.33) 0.27 (0.18–0.33) 0.368 0.33 (0.02–3.36)
1995 0.29 (0.18–0.43) 0.30 (0.15–0.46) 0.990 1.00 (0.46–2.13)
2011 0.31 (0.22–0.38) 0.36 (0.24–0.48) 0.023 36.19 (2.20–1109.21)
CT667 2006 0.04 (0.03–0.06) 0.04 (0.03–0.07) 0.169 2766.28 (0.06–6.20 × 108)
1995 0.14 (0.05–0.23) 0.12 (0.03–0.23) 0.344 0.59 (0.18–1.68)
2011 0.03 (0.02–0.06) 0.03 (0.02–0.07) 0.802 0.23 (2.47 × 10-6–24,634.90)
CT706 2006 0.05 (0.03–0.07) 0.04 (0.03–0.06) 0.289 42.59 (0.07–1.26 × 105)
1995 0.14 (0.06–0.23) 0.12 (0.04–0.23) 0.307 0.58 (0.18–1.57)
2011 0.02 (0.02–0.06) 0.03 (0.02–0.08) 0.940 1.24 (0.005–619.41)
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of sera. These results suggest the differentially recog-
nised antigens identified are likely false-positive artefacts
from screening of small numbers of sera on the array.
CT442 is an example of where one or two individuals
with high levels of antibody against an antigen skewed
the results in the small data set. This highlights the need
for validation and follow-up of antibody targets identi-
fied through related high-throughput techniques.
Conclusions
Antibody responses against Ct antigens were focussed in
adults. There was considerable homogeneity between
those with and without conjunctival scarring. Antibody re-
sponses were focussed on antigens expressed early and
late in the Ct developmental cycle and localised to the
outer membrane or secreted. Only nine antigens were dif-
ferentially recognised between the two groups, of which
only one (CT442) was inconsistently associated with a
lack of scarring. Understanding how these antigens be-
come antibody targets and how this could impact scarring
is difficult due to limited localisation and functional infor-
mation. Heterogenous responses in the studies examined
here highlight the need for large sample sizes and clearly
defined clinical phenotypes in human studies of humoral
immunity to reduce the influence of outliers. Immunoge-
netic information would further aid understanding of the
observed heterogeneity in antibody responses.
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